JP2014529629A5 - - Google Patents

Download PDF

Info

Publication number
JP2014529629A5
JP2014529629A5 JP2014528963A JP2014528963A JP2014529629A5 JP 2014529629 A5 JP2014529629 A5 JP 2014529629A5 JP 2014528963 A JP2014528963 A JP 2014528963A JP 2014528963 A JP2014528963 A JP 2014528963A JP 2014529629 A5 JP2014529629 A5 JP 2014529629A5
Authority
JP
Japan
Prior art keywords
chem
xaa
lys
linker
derivative according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014528963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014529629A (ja
JP6126097B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/067364 external-priority patent/WO2013037690A1/en
Publication of JP2014529629A publication Critical patent/JP2014529629A/ja
Publication of JP2014529629A5 publication Critical patent/JP2014529629A5/ja
Application granted granted Critical
Publication of JP6126097B2 publication Critical patent/JP6126097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014528963A 2011-09-06 2012-09-06 Glp−1誘導体 Active JP6126097B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11180265 2011-09-06
EP11180265.8 2011-09-06
US201161532323P 2011-09-08 2011-09-08
US61/532,323 2011-09-08
PCT/EP2012/067364 WO2013037690A1 (en) 2011-09-06 2012-09-06 Glp-1 derivatives

Publications (3)

Publication Number Publication Date
JP2014529629A JP2014529629A (ja) 2014-11-13
JP2014529629A5 true JP2014529629A5 (enExample) 2015-10-01
JP6126097B2 JP6126097B2 (ja) 2017-05-10

Family

ID=47882647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528963A Active JP6126097B2 (ja) 2011-09-06 2012-09-06 Glp−1誘導体

Country Status (6)

Country Link
US (2) US9758560B2 (enExample)
EP (1) EP2753642B8 (enExample)
JP (1) JP6126097B2 (enExample)
CN (2) CN104039822A (enExample)
ES (1) ES2626013T3 (enExample)
WO (1) WO2013037690A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
JP6366575B2 (ja) * 2012-05-08 2018-08-01 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
LT3004155T (lt) * 2013-05-28 2021-12-27 Takeda Pharmaceutical Company Limited Peptidų junginys
ES2741507T3 (es) * 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
KR20180135012A (ko) * 2016-04-28 2018-12-19 노보 노르디스크 에이/에스 심혈관 병태에서의 세마글루타이드
CN109477094B (zh) 2016-05-24 2022-04-26 武田药品工业株式会社 肽化合物
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
ES2980707T3 (es) 2018-04-05 2024-10-02 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1
CN110386975B (zh) * 2018-04-19 2021-06-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
FI4097099T3 (fi) 2020-02-07 2024-07-30 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
PL4143183T3 (pl) 2020-04-29 2026-03-02 Gasherbrum Bio, Inc. Heterocykliczni agoniści glp-1
CN113292646B (zh) * 2020-05-29 2022-05-13 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
MX2023001311A (es) 2020-08-06 2023-04-18 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1.
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー,リミテッド ポリペプチドコンジュゲートおよび使用の方法
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
CN114621340B (zh) * 2022-03-11 2022-09-23 北京惠之衡生物科技有限公司 一种酰化的长效glp-1衍生物
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN114958883B (zh) * 2022-04-12 2023-01-31 北京惠之衡生物科技有限公司 一种表达glp-1类似物的重组工程菌及其构建方法
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250110330A (ko) * 2022-11-21 2025-07-18 일라이 릴리 앤드 캄파니 Gip/glp1 이중 효능제의 제조 방법
JP2026502644A (ja) * 2023-01-23 2026-01-23 クロスケム・リミテッド ケラチン処理用化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
DK0573551T3 (da) 1991-02-27 2003-08-04 Micromet Ag Serinrige peptidlinkere
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
CA2136078A1 (en) 1992-12-04 1994-06-23 Jonathan Greer 6-position modified decapeptide lhrh antagonists
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5663907A (en) * 1996-04-25 1997-09-02 Bright Microelectronics, Inc. Switch driver circuit for providing small sector sizes for negative gate erase flash EEPROMS using a standard twin-well CMOS process
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO1999043706A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
BRPI0417684A (pt) * 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
KR20070004078A (ko) 2004-03-31 2007-01-05 센토코 인코포레이티드 인간 glp-1 모방체, 조성물, 방법 및 용도
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN104327182B (zh) * 2009-12-16 2020-04-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
CN105601729A (zh) 2010-11-09 2016-05-25 诺沃—诺迪斯克有限公司 双-酰化的glp-1衍生物
JP6366575B2 (ja) 2012-05-08 2018-08-01 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体

Similar Documents

Publication Publication Date Title
JP2014529629A5 (enExample)
JP2013543853A5 (enExample)
JP2014501712A5 (enExample)
RU2013148921A (ru) Дважды ацилированные производные glp-1
JP2015517478A5 (enExample)
JP2017514801A5 (enExample)
JP2015517477A5 (enExample)
JP2016523243A5 (enExample)
JP2010538049A5 (enExample)
JP2017105819A5 (enExample)
JP2016529253A5 (enExample)
JP2013517307A5 (enExample)
JP2014503526A5 (enExample)
US11167014B2 (en) Solid glp-1 derivative compositions for oral administration
JP2018506507A5 (enExample)
CN107812181B (zh) Glp-1肽组合物及其制备
JP5969461B2 (ja) Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
JP2008533105A5 (enExample)
JP2005528337A5 (enExample)
JP7432361B2 (ja) ヒトインスリンまたはそのアナログのアシル化誘導体
JP2016526012A5 (enExample)
JP2019513126A5 (enExample)
EP2844269A1 (en) Transmucosal delivery of engineered polypeptides
JP2010529004A5 (enExample)
JP2010515677A5 (enExample)